JP7605747B2 - 修飾されたgipペプチド類似体 - Google Patents

修飾されたgipペプチド類似体 Download PDF

Info

Publication number
JP7605747B2
JP7605747B2 JP2021552785A JP2021552785A JP7605747B2 JP 7605747 B2 JP7605747 B2 JP 7605747B2 JP 2021552785 A JP2021552785 A JP 2021552785A JP 2021552785 A JP2021552785 A JP 2021552785A JP 7605747 B2 JP7605747 B2 JP 7605747B2
Authority
JP
Japan
Prior art keywords
gip
seq
amino acid
peptide
functional variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509568A (ja
JP2022509568A5 (cg-RX-API-DMAC7.html
Inventor
スパール‐ウリッチ,アレクサンダー,ホヴァード
シヴァースン,ビアン,ビエンズ
リバー,ディッテ
ロースンキーレ,メッテ,マリー
Original Assignee
アンタグ セラピューティクス エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンタグ セラピューティクス エーピーエス filed Critical アンタグ セラピューティクス エーピーエス
Publication of JP2022509568A publication Critical patent/JP2022509568A/ja
Publication of JP2022509568A5 publication Critical patent/JP2022509568A5/ja
Application granted granted Critical
Publication of JP7605747B2 publication Critical patent/JP7605747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021552785A 2018-12-03 2019-12-03 修飾されたgipペプチド類似体 Active JP7605747B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18209896 2018-12-03
EP18209896.2 2018-12-03
EP19176739 2019-05-27
EP19176739.1 2019-05-27
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues

Publications (3)

Publication Number Publication Date
JP2022509568A JP2022509568A (ja) 2022-01-20
JP2022509568A5 JP2022509568A5 (cg-RX-API-DMAC7.html) 2022-12-07
JP7605747B2 true JP7605747B2 (ja) 2024-12-24

Family

ID=68731999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552785A Active JP7605747B2 (ja) 2018-12-03 2019-12-03 修飾されたgipペプチド類似体

Country Status (12)

Country Link
US (3) US12187773B2 (cg-RX-API-DMAC7.html)
EP (2) EP3891174A1 (cg-RX-API-DMAC7.html)
JP (1) JP7605747B2 (cg-RX-API-DMAC7.html)
KR (2) KR102906485B1 (cg-RX-API-DMAC7.html)
CN (3) CN113366014B (cg-RX-API-DMAC7.html)
AU (2) AU2019391300B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010447A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121043A1 (cg-RX-API-DMAC7.html)
IL (1) IL283385A (cg-RX-API-DMAC7.html)
MX (1) MX2021006505A (cg-RX-API-DMAC7.html)
SG (1) SG11202105586YA (cg-RX-API-DMAC7.html)
WO (2) WO2020115049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122520749A (zh) * 2019-12-03 2026-08-07 安泰博医药 优化的gip肽类似物
WO2022007809A1 (zh) * 2020-07-06 2022-01-13 鸿绪生物医药科技(北京)有限公司 新型多肽制剂及其治疗用途
AU2021304762B2 (en) * 2020-07-06 2024-05-02 Vitalixir (Beijing) Co., Ltd Novel polypeptide and therapeutic use thereof
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
MX2023014740A (es) * 2021-06-10 2024-03-13 Antag Therapeutics Aps Tratamiento de la obesidad y trastornos relacionados con la obesidad.
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023139106A2 (en) 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
CN117402219B (zh) 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
CN118255864A (zh) * 2022-12-26 2024-06-28 杭州中美华东制药有限公司 Gip受体激动剂及其用途
CN116120425A (zh) * 2022-12-27 2023-05-16 南京赛诺生物技术有限公司 一种glp-1/gip受体双重激动剂及其应用
GB202302686D0 (en) * 2023-02-24 2023-04-12 Imperial College Innovations Ltd Novel compounds
AU2024224775A1 (en) * 2023-02-24 2025-10-09 Ip2Ipo Innovations Limited Compounds
WO2024209050A1 (en) * 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
AR134436A1 (es) * 2023-11-22 2026-01-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025176999A2 (en) * 2024-02-23 2025-08-28 Ip2Ipo Innovations Limited Novel compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ,インコーポレイテッド Gip類似体および選択可能な特性を備えるハイブリッドポリペプチド
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5745335A (en) 1996-06-27 1998-04-28 Gennum Corporation Multi-layer film capacitor structures and method
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
JP3270761B2 (ja) 1998-01-30 2002-04-02 ノボ ノルディスク アクティーゼルスカブ 注射器
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69918070T2 (de) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
DE69926007T2 (de) 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
ATE272650T1 (de) 1999-03-29 2004-08-15 Uutech Ltd Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
ATE347764T1 (de) 2001-09-21 2006-12-15 Koninkl Philips Electronics Nv Gibt es kein spezifisches kontrollmodul? benutzen sie eines das weniger spezifisch ist
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
CA2732949C (en) 2008-08-07 2016-12-20 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
KR20130133103A (ko) 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체
CA2733005C (en) 2008-08-07 2016-09-27 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (es) 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
KR102002783B1 (ko) * 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
ES2602486T3 (es) * 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
US10774127B2 (en) 2016-10-12 2020-09-15 University Of Copenhagen Peptide dual agonists of GIPR and GLP2R
EP3556399A1 (en) * 2016-12-19 2019-10-23 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
WO2018124011A1 (ja) 2016-12-26 2018-07-05 花王株式会社 運動調節機能向上剤
US20190330332A1 (en) 2016-12-26 2019-10-31 Kao Corporation Hypothermia Ameliorating Agent
EP3569248B1 (en) 2016-12-26 2023-12-06 Kao Corporation Gip inhibitors for improving cognitive function
US11572399B2 (en) * 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ,インコーポレイテッド Gip類似体および選択可能な特性を備えるハイブリッドポリペプチド
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Diabetologia,2015年,Vol.58,p.2144-2153
J.Med. Chem.,2006年,Vol.49,p.1047-1054
Molecular and Cellular Endocrinology,2015年,Vol.401,p.120-129

Also Published As

Publication number Publication date
MX2021006505A (es) 2021-10-01
KR102906485B1 (ko) 2025-12-31
SG11202105586YA (en) 2021-06-29
CN113366014B (zh) 2025-10-21
AU2025237957A1 (en) 2025-10-16
EP3891174A1 (en) 2021-10-13
KR20260011770A (ko) 2026-01-23
US20250376499A1 (en) 2025-12-11
US12297250B2 (en) 2025-05-13
US20220025010A1 (en) 2022-01-27
IL283385A (en) 2021-07-29
CA3121043A1 (en) 2020-06-11
WO2020115048A1 (en) 2020-06-11
AU2019391300B2 (en) 2025-06-26
CN121449721A (zh) 2026-02-03
CN113366014A (zh) 2021-09-07
AU2019391300A1 (en) 2021-07-01
EP3891173A1 (en) 2021-10-13
US20220298218A1 (en) 2022-09-22
JP2022509568A (ja) 2022-01-20
US12187773B2 (en) 2025-01-07
CN121449720A (zh) 2026-02-03
WO2020115049A1 (en) 2020-06-11
BR112021010447A2 (pt) 2021-08-24
KR20210102911A (ko) 2021-08-20

Similar Documents

Publication Publication Date Title
US20250376499A1 (en) Modified gip peptide analogues
JP7788376B2 (ja) 最適化されたgipペプチド類縁体
CN110691788B (zh) 长效gip肽类似物
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
RU2858286C2 (ru) Оптимизированные пептидные аналоги gip
CA3064510C (en) Long-acting gip peptide analogues
WO2024003359A1 (en) AMYLIN RECEPTOR (hAMY3R) AGONISTS WITH IMPROVED CHEMICAL STABILITY

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241212

R150 Certificate of patent or registration of utility model

Ref document number: 7605747

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150